2012 DNA Immune Response Therapies 
PLOS: DNA Science
OCTOBER 12, 2023
In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.
Drug Target Review
OCTOBER 26, 2023
Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
NOVEMBER 6, 2023
2 It is this complexity that necessitates powerful, targeted combination therapies. 4, 5 More recently, new combination regimens have emerged that incorporate targeted therapies to treat a variety of blood cancers, including multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and acute myelogenous leukaemia (AML).
Drug Target Review
OCTOBER 4, 2023
2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour.
Drug Discovery World
OCTOBER 21, 2022
DNA-based dyes, amine-reactive, fixable dyes) as oversaturated staining can falsely lead to over-exclusion of live cells from analysis. . After initial postgraduate studies at Gothenburg University, he continued his academic career at UCSD characterising the innate immune response against pathogens. Future directions .
Expert insights. Personalized for you.
69 
Let's personalize your content